Press coverage about Juniper Pharmaceuticals (NASDAQ:JNP) has trended somewhat positive this week, according to Accern Sentiment Analysis. Accern identifies negative and positive media coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Juniper Pharmaceuticals earned a news impact score of 0.15 on Accern’s scale. Accern also gave news coverage about the specialty pharmaceutical company an impact score of 44.1814115913638 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
Shares of Juniper Pharmaceuticals (NASDAQ:JNP) traded up $0.07 during mid-day trading on Friday, hitting $5.98. 18,534 shares of the stock were exchanged, compared to its average volume of 48,643. Juniper Pharmaceuticals has a 12-month low of $3.65 and a 12-month high of $6.40. The company has a debt-to-equity ratio of 0.08, a quick ratio of 1.68 and a current ratio of 2.00. The company has a market cap of $64.79, a P/E ratio of 10.13 and a beta of 0.04.
JNP has been the subject of a number of recent research reports. HC Wainwright reissued a “neutral” rating on shares of Juniper Pharmaceuticals in a research report on Monday, November 6th. Roth Capital initiated coverage on shares of Juniper Pharmaceuticals in a research report on Tuesday, January 2nd. They set a “buy” rating and a $12.00 price objective for the company. Finally, ValuEngine raised shares of Juniper Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Monday, October 2nd. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and two have given a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average price target of $23.00.
TRADEMARK VIOLATION WARNING: This story was first posted by Stock Observer and is the sole property of of Stock Observer. If you are reading this story on another site, it was stolen and reposted in violation of United States and international trademark & copyright law. The original version of this story can be viewed at https://www.thestockobserver.com/2018/01/14/juniper-pharmaceuticals-jnp-earning-somewhat-positive-press-coverage-analysis-shows.html.
Juniper Pharmaceuticals Company Profile
Juniper Pharmaceuticals, Inc is a women’s health therapeutics company. The Company is focused on developing therapeutics that address unmet medical needs in women’s health. It operates in two segments: product and service. The product segment is engaged in manufacturing and supplying CRINONE, the Company’s commercialized product.
Receive News & Ratings for Juniper Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juniper Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.